US4452790A - Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives - Google Patents
Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives Download PDFInfo
- Publication number
- US4452790A US4452790A US06/391,884 US39188482A US4452790A US 4452790 A US4452790 A US 4452790A US 39188482 A US39188482 A US 39188482A US 4452790 A US4452790 A US 4452790A
- Authority
- US
- United States
- Prior art keywords
- lower alkyl
- hydrogen
- carbons
- sub
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
Definitions
- Petrillo in U.S. Pat. No. 4,168,267 discloses that various phosphinylalkanoyl substituted prolines are useful as hypotensive agents due to their ability to inhibit the angiotensin converting enzyme.
- Ondetti et al. in U.S. Pat. No. 4,151,172 disclose that various phosphonoacyl prolines are useful as hypotensive agents due to their ability to inhibit the angiotensin converting enzyme.
- Mercaptoacyl derivatives of 3,4-dehydroproline are disclosed as angiotensin converting enzyme inhibitors by Ondetti in U.S. Pat. No. 4,129,566.
- Mercaptoacyl derivatives of thiazolidinecarboxylic acid and substituted thiazolidinecarboxylic acid are disclosed as angiotensin converting enzyme inhibitors by Ondetti in U.S. Pat. No. 4,192,878 and by Yoshitomo Pharmaceutical Ind. in Belgian Patent No. 868,532.
- This invention is directed to new phosphonate substituted amino or imino acids of formula I and salts thereof ##STR2##
- X is an imino or amino acid of the formula ##STR3##
- R 4 is hydrogen, lower alkyl, halogen, keto, hydroxy, ##STR4## a 1- or 2-naphthyl of the formula ##STR5## a 1- or 2-naphthyloxy of the formula ##STR6## or a 1- or 2-naphthylthio of the formula ##STR7##
- R 5 is keto, halogen, ##STR8## --O--lower alkyl, a 1- or 2-naphthyloxy of the formula ##STR9## --S--lower alkyl, ##STR10## or a 1- or 2-naphthylthio of the formula ##STR11##
- R 7 is keto or ##STR12##
- Each R 8 is independently halogen or --Y--R 14 .
- R 9 , R 9 ', R 10 and R 10 ' are independently selected from hydrogen and lower alkyl or R 9 ', R 10 and R 10 ' are hydrogen and R 9 is ##STR13##
- R 11 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl.
- R 12 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy.
- n is zero, one, two or three.
- p is one, two or three provided that p is more than one only if R 11 or R 12 is hydrogen, methyl, methoxy, chloro, or fluoro.
- R 13 is hydrogen or lower alkyl of 1 to 4 carbons.
- Y is oxygen or sulfur.
- R 14 is lower alkyl of 1 to 4 carbons, ##STR14## or the R 14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di(lower alkyl of 1 to 4 carbons) substituent.
- R 21 is hydrogen, lower alkyl, cycloalkyl, phenyl, or ##STR15##
- R 22 is hydrogen, lower alkyl, ##STR16##
- r is an integer from 1 to 4.
- R 1 is alkyl of 1 to 10 carbons, aminoalkyl, haloalkyl, ##STR17## wherein q is zero or an integer from 1 to 7 and R 12 and p are as defined above.
- R 19 and R 20 are independently selected from hydrogen, lower alkyl, halo substituted lower alkyl, ##STR18## wherein m, R 11 , and p are as defined above.
- R 2 is hydrogen, lower alkyl, halo substituted lower alkyl, ##STR19## wherein r is as defined above.
- R 3 and R 6 are independently selected from hydrogen, lower alkyl, benzyl, alkali metal such as Li, Na or K, benzhydryl, or ##STR20## wherein R 15 is hydrogen, lower alkyl, cycloalkyl, or phenyl, and R 16 is hydrogen, lower alkyl, lower alkoxy, phenyl, or R 15 and R 16 taken together are --(CH 2 ) 2 --, --(CH 2 ) 3 --, --CH ⁇ CH--, or ##STR21##
- R 17 is lower alkyl, benzyl, or phenethyl.
- R 18 is hydrogen, lower alkyl, benzyl or phenethyl.
- This invention in its broadest aspects relates to the phosphonate substituted imino or amino acid compounds of formula I above, to compositions containing such compounds and to the method of using such compounds as anti-hypertensive agents.
- alkyl used in defining R 1 refers to straight or branched chain hydrocarbon radicals having up to ten carbons, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, heptyl, octyl, decyl, etc.
- lower alkyl used in defining various symbols refers to straight or branched chain radicals having up to seven carbons.
- the preferred lower alkyl groups are up to four carbons with methyl and ethyl most preferred.
- lower alkoxy and lower alkylthio refer to such lower alkyl groups attached to an oxygen or sulfur.
- cycloalkyl refers to saturated rings of 3 to 7 carbon atoms with cyclopentyl and cyclohexyl being most preferred.
- halo refers to Cl, Br and F.
- halo substituted lower alkyl refers to such lower alkyl groups described above in which one or more hydrogens have been replaced by chloro, bromo or fluoro groups such as trifluoromethyl, which is preferred, pentafluoroethyl, 2,2,2-trichloroethyl, chloromethyl, bromomethyl, etc.
- amino substituted lower alkyl refers to lower alkyl groups in which one or more hydrogens have been replaced by --NH 2 , i.e., aminomethyl, 2-aminoethyl, etc.
- the symbols ##STR22## represent that the alkylene bridge is attached to an available carbon atom.
- the acid VI or its activated form is then coupled with an imino or amino acid or ester of the formula ##STR29##
- activated form refers to the conversion of the acid to a mixed anhydride, symmetrical anhydride, acid chloride, or activated ester, see Methoden der Organischen Chemie (Houben-Weyl), Vol. XV, part II, page 1 et seq. (1974) for a review of the methods of acylation.
- the reaction is performed in the presence of a coupling agent such as 1,1-carbonyldiimidazole, thionyl chloride, or dicyclohexylcarbodiimide.
- R 2 is ##STR30## then the hydroxyl, amino, imidazolyl, mercaptan, or guanidinyl function should be protected during the coupling reaction.
- Suitable protecting groups include benzyloxycarbonyl, t-butoxycarbonyl, benzyl, benzhydryl, trityl, etc., and nitro in the case of guanidinyl.
- the protecting group is removed by hydrogenation, treatment with acid, or other known methods following completion of the reaction.
- the products of formula I wherein either or both of R 3 and R 6 are lower alkyl, benzyl, or benzhydryl can be hydrogenated, for example, by treating with hydrogen in the presence of a palladium on carbon catalyst or chemically treated such as with sodium hydroxide in aqueous dioxane or with trimethylsilylbromide in dichloromethane to yield the products of formula I wherein R 3 and R 6 are hydrogen.
- ester products of formula I wherein R 6 is ##STR31## may be obtained by employing the imino or amino acid of formula V in the above reactions with the ester group already in place.
- ester reactants can be prepared by treating peptide, imino, or amino acids with an acid chloride such as ##STR32## so as to protect the N-atom.
- the protected acid compound is then reacted in the presence of base with a compound of the formula ##STR33## wherein L is a leaving group such as chlorine, bromine, tolylsulfonyloxy, etc., followed by removal of the N-protecting group such as by treatment with acid or hydrogenation.
- ester products of formula I wherein R 6 is ##STR34## can also be obtained by treating the product of formula I wherein R 6 is hydrogen with a molar equivalent of the compound of formula VIII.
- the diester products wherein R 3 and R 6 are the same and are ##STR35## can be obtained by treating the product of formula I wherein R 3 and R 6 are both hydrogen or an alkali metal salt with two or more equivalents of the compound of formula VIII.
- ester products of formula I wherein R 3 is ##STR36## can be obtained by treating the product of formula I wherein R 3 is hydrogen or an alkali metal salt and R 6 is benzyl or benzhydryl with the compound of formula VIII in the presence of base. Removal of the R 6 ester group such as by hydrogenation yields the products of formula I wherein R 3 is ##STR37## and R 6 is hydrogen.
- esters where R 6 is t-butyl can be obtained by treating the corresponding N-carbobenzyloxyimino acid with isobutylene under acidic conditions and then removing the N-carbobenzyloxy protecting group by catalytic hydrogenation and the esters wherein R 6 is benzyl can be obtained by treating the imino acid with benzyl alcohol and thionyl chloride.
- the substituted prolines wherein R 4 is ##STR38## are prepared by reacting a 4-keto proline of the formula ##STR39## with a solution of the Grignard or lithium reagent ##STR40## wherein R 4 is as defined above and halo is Br or Cl to yield ##STR41##
- This compound is treated with a dehydrating agent such as p-toluenesulfonic acid, sulfuric acid, potassium bisulfate, or trifluoroacetic acid to yield the 3,4-dehydro-4-substituted proline of the formula ##STR42## Removal of the N-benzyloxycarbonyl protecting group and hydrogenation of the compound of formula XII yields the desired starting materials.
- the substituted proline wherein R 4 is cyclohexyl can be prepared by further hydrogenation of the 4-phenyl proline compound.
- substituted prolines wherein R 4 is the substituted amino group ##STR43## may be prepared by reacting a 4-keto proline of formula IX with the amine ##STR44## in the presence of hydrogen and catalyst or in the presence of sodium cyanotrihydridoborate.
- the compounds of formula I wherein R 1 is ##STR45## that is ##STR46## may be prepared by reacting an aminophosphonic acid of the formula ##STR47## with an acid chloride having the formula ##STR48## such as benzoyl chloride, in the presence of an inert organic solvent, such as dioxane and a weak organic base, such as triethylamine to yield ##STR49##
- the formula XVI compound is then coupled with an imino or amino acid or ester of formula XVII ##STR50## in the presence of a coupling agent, such as dicyclohexylcarbodiimide as described above to form ##STR51##
- X includes a protecting group
- it may be removed by hydrogenation wherein the protecting group is phenylmethoxycarbonyl or by treatment with hydrazine where the protecting group is phthalidyl to yield the compounds of formula XIII.
- the compounds of formula XVII may be prepared by coupling a hydroxy acid of formula XIX as the free acid or corresponding sodium salt ##STR52## with an imino or amino ester of formula VII preferably in the presence of a coupling agent such as diphenyl phosphorylazide.
- Preferred compounds of this invention with respect to the amino or imino acid or ester part of the structure of formula I are those wherein:
- R 21 is hydrogen, methyl, phenyl, cyclopentyl or cyclohexyl
- R 22 is hydrogen, lower alkyl of 1 to 4 carbons, ##STR53##
- R 6 is hydrogen, an alkali metal salt, or ##STR54##
- R 15 is hydrogen, methyl or isopropyl and R 16 is straight or branched chain lower alkyl of 1 to 4 carbons or phenyl.
- R 4 is hydrogen
- R 4 is hydroxy
- R 4 is chloro or fluoro.
- R 4 is lower alkyl of 1 to 4 carbons or cyclohexyl.
- R 4 is amino
- R 4 is --O--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
- R 4 is ##STR55## wherein m is zero, one or two, R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
- R 4 is ##STR56## 1-naphthyloxy, or 2-naphthyloxy wherein m is zero, one or two, and R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
- R 4 is --S--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
- R 4 is ##STR57## 1-naphthylthio, or 2-naphthylthio wherein m is zero, one or two, and R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
- R 5 is --O--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
- R 5 is ##STR58## wherein m is zero, one or two, and R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
- R 5 is --S--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
- R 5 is ##STR59## wherein m is zero, one or two, and R 12 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
- R 7 is phenyl, 2-hydroxyphenyl, or 4-hydroxyphenyl.
- Each R 8 is independently fluoro or chloro.
- Each R 8 is independently --Y--R 14 wherein Y is O or S, R 14 is straight or branched chain alkyl of 1 to 4 carbons or the R 14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a methyl or dimethyl substituent.
- R 9 , R 9 ', R 10 and R 10 ' are all hydrogen, or R 9 is phenyl, 2-hydroxyphenyl or 4-hydroxyphenyl and R 9 ', R 10 and R 10 ' are hydrogen.
- R 6 is hydrogen, ##STR61## or an alkali metal salt.
- R 4 is hydrogen
- R 4 is cyclohexyl
- R 4 is lower alkoxy of 1 to 4 carbons.
- R 4 is ##STR62## wherein m is zero, one, or two and R 11 is hydrogen, methyl, methoxy, methylthio, Cl, Br, F or hydroxy.
- Y is oxygen or sulfur and t is two or three, especially wherein Y is sulfur and t is two.
- Preferred compounds of this invention with respect to the phosphonyl sidechain of the structure of formula I are those wherein:
- R 2 is hydrogen, lower alkyl of 1 to 4 carbons, CF 3 , or amino substituted lower alkyl of 1 to 4 carbons, especially hydrogen, methyl or --(CH 2 ) 4 NH 2 .
- R 3 is hydrogen, an alkali metal salt, lower alkyl of 1 to 4 carbons, or ##STR63## wherein R 15 is hydrogen, methyl or isopropyl and R 16 is straight or branched chain lower alkyl of 1 to 4 carbons or phenyl, especially hydrogen, alkali metal salt, ethyl, ##STR64##
- R 1 is alkyl of 1 to 10 carbons; ##STR65## wherein q is zero or an integer from 1 to 4 and R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy; --(CH 2 ) q -- cycloalkyl wherein cycloalkyl is of 5 or 6 carbons and q is zero, one or two; ##STR66## wherein q is zero or an integer from 1 to 4, ##STR67## wherein q is zero or an integer from 1 to 4, ##STR68## wherein q is zero or an integer from 1 to 4 or ##STR69##
- R 19 and R 20 are independently selected from lower alkyl of 1 to 4 carbons or ##STR70## wherein q is zero or an integer from 1 to 4 and R 11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy, especially wherein R 19 is phenylethyl and R 20 is phenyl.
- the compounds of this invention wherein at least one of R 3 or R 6 is hydrogen form basic salts with various inorganic and organic bases which are also within the scope of the invention.
- Such salts include ammonium salts, alkali metal salts like lithium, sodium and potassium salts (which are preferred), alkaline earth metal salts like calcium and magnesium salts, salts with organic bases, e.g., dicyclohexylamine salt, benzathine, N-methyl-D-glucamine, hydrabamine salts, salts with amino acids like arginine, lysine and the like.
- the nontoxic physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product.
- the salts are formed using conventional techniques.
- the amino or imino acid or ester portion of the molecule of the products of formula I represented by X is in the L-configuration.
- R 2 and R 19 other asymmetric center may be present in the phosphonyl sidechain.
- some of the compounds can accordingly exist in diastereoisomeric forms or in mixtures thereof.
- the above described processes can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric products are prepared, they can be separated by conventional chromatographic or fractional crystallization methods.
- the compounds of formula I are hypotensive agents. They inhibit the conversion of the decapeptide angiotensin I to angiotensin II and, therefore, are useful in reducing or relieving angiotensin related hypertension.
- Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II.
- ACE angiotensin converting enzyme
- the latter is an active pressor substance which has been implicated as the causative agent in several forms of hypertension in various mammalian species, e.g., humans.
- the compounds of this invention intervene in the angiotensinogen ⁇ (renin) ⁇ angiotensin I ⁇ angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II.
- a composition containing one (or a combination) of the compounds of this invention angiotensin dependent hypertension in a species of mammal (e.g., humans) suffering therefrom is alleviated.
- a single dose, or preferably two or four divided daily doses, provided on a basis of about 0.1 to 100 mg per kilogram of body weight per day is appropriate to reduce blood pressure.
- the substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes can also be employed.
- the compounds of this invention can also be formulated in combination with a diuretic for the treatment of hypertension.
- a combination product comprising a compound of this invention and a diuretic can be administered in an effective amount which comprises a total daily dosage of about 30 to 600 mg., preferably about 30 to 330 mg of a compound of this invention, and about 15 to 300 mg, preferably about 15 to 200 mg of the diuretic, to a mammalian species in need thereof.
- Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds.
- thiazide diuretics e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichloromethiazide, polythiazide or
- the compounds of formula I can be formulated for use in the reduction of blood pressure in compositions such as tablets, capsules or elixirs for oral administration, or in sterile solutions or suspensions for parenteral administration.
- compositions such as tablets, capsules or elixirs for oral administration, or in sterile solutions or suspensions for parenteral administration.
- About 10 to 500 mg of a compound of formula I is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservatives, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice.
- the amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
- AG-50W-X8 refers to a crosslinked polystyrenedivinylbenzene sulfonic acid cation exchange resin.
- HP-20 refers to a porous crosslinked polystyrene-divinyl benzene polymer resin.
- Example 1 Following the procedure of Example 1 but employing the phosphonic acid shown in Col. I, the lactate shown in Column II, the imino acid or amino acid or ester in Col. III, and the alcohol R 3 OH, one obtains the diester shown in Col. IV. Both the R 3 and R 6 ester groups may be removed to yield the corresponding diacid or salt as set forth in Example 1E or only the carboxylic ester group R 6 may be removed or in the case of Examples 77-87 only the R 3 ester group may be removed.
- Example 2 Following the procedure of Example 2 but employing the phosphonic acid shown in Col. I, the acid chloride shown in Col. II, and the hydroxyacyl imino ester shown in Col. III, one obtains the intermediate shown in Col. IV. Removal of the carboxylic acid protecting group yields the compound of Col. V which can be treated to obtain a salt as shown in Example 2, Part E.
- a mixture of the benzyl ester from Part A (1.03 g, 2.0 mmole) 10% Pd/C (0.20 g) and methanol (50 ml) is hydrogenated on a Parr apparatus at a pressure of 50 psi for 3 hours.
- the catalyst is removed by filtration through celite and the filtrate evaporated to dryness to give the title compound.
- alkylating agents of Examples 125-130 can be employed with the appropriately protected compounds of Examples 1 to 124 to yield other compounds within the scope of this invention.
- the proline carboxyl group is protected as its phenylmethyl ester rather than its t-butyl ester, it is removed by hydrogenation in the presence of Pd/C in the final step.
- tablets containing 100 mg of the product of any of Examples 2 to 130 can be prepared.
- tablets containing 50 mg of the product of any of Examples 1 and 3 to 130 can be prepared.
- Two piece #1 gelatin capsules each containing 100 mg of 1-[(S)-2-[[[( ⁇ )-1-(benzoylamino)-3-phenylpropyl]phosphinyl]oxy]-1-oxopropyl]-L-proline, sodium salt are filled with a mixture of the following ingredients:
- capsules containing 100 mg of the product of any of Examples 1 and 3 to 130 can be prepared.
- An injectable solution is prepared as follows:
- the active substance, preservatives, and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters.
- the solution is filtered through a sterile filter and asceptically filled into presterilized vials which are closed with presterilized rubber closures.
- Each vial contains 5 ml of solution in a concentration of 100 mg of active ingredient per ml of solution for injection.
- an injectable solution containing 100 mg of active ingredient per ml of solution can be prepared for the product of any of Examples 2 to 130.
- tablets can be prepared containing 100 mg of the product of any of Examples 2 to 130.
Abstract
Phosphonyl hydroxyacyl amino acids of the formula <IMAGE> wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.
Description
Thorsett, et al. in U.S. Pat. No. 4,316,896 disclose phosphoryl derivatives of aminoacids including proline. These compounds are disclosed as being hypotensive agents due to their angiotensin converting enzyme inhibition activity.
Petrillo in U.S. Pat. No. 4,168,267 discloses that various phosphinylalkanoyl substituted prolines are useful as hypotensive agents due to their ability to inhibit the angiotensin converting enzyme.
Ondetti et al. in U.S. Pat. No. 4,151,172 disclose that various phosphonoacyl prolines are useful as hypotensive agents due to their ability to inhibit the angiotensin converting enzyme.
Mercaptoacyl derivatives of proline and substituted prolines are known to be useful hypotensive agents due to their angiotensin converting enzyme inhibition activity. Ondetti et al. in U.S. Pat. No. 4,105,776 disclose such compounds wherein the proline ring is unsubstituted or substituted by an alkyl or hydroxy group. Ondetti et al. in U.S. Pat. No. 4,154,935 disclose such compounds wherein the proline ring is substituted with one or more halogens. Ondetti et al. in U.K. Patent Application No. 2,028,327 disclose such compounds wherein the proline ring is substituted by various ethers and thioethers. Krapcho in U.S. Pat. No. 4,217,359 discloses such compounds wherein the proline ring has a carbamoyloxy substituent. Krapcho in U.K. Patent Application No. 2,039,478 discloses compounds wherein the proline ring has a diether, dithioether, ketal or thioketal substituent in the 4-position. Krapcho in U.S. Pat. No. 4,316,905 discloses such compounds wherein the proline ring has a cycloalkyl, phenyl, or phenyl-lower alkylene substituent. Ondetti et al. in U.S. Pat. No. 4,234,489 disclose such compounds wherein the proline has a keto substituent in the 5-position. Krapcho et al. in U.S. Pat. No. 4,310,461 disclose such compounds wherein the proline has an imido, amido, or amino substituent in the 4-position. Iwao et al. in U.K. Patent Application No. 2,027,025 disclose such compounds wherein the proline has an aromatic substituent in the 5-position. Ondetti et al. in U.S. Pat. Nos. 4,053,651 and 4,199,512 disclose that mercaptoacyl derivatives of various aminoacids other than proline are also useful angiotensin converting enzyme inhibitors.
Karanewsky and Petrillo in U.S. Ser. No. 289,671 disclose phosphonamidate substituted amine or imino acids.
Mercaptoacyl derivatives of 3,4-dehydroproline are disclosed as angiotensin converting enzyme inhibitors by Ondetti in U.S. Pat. No. 4,129,566. Mercaptoacyl derivatives of thiazolidinecarboxylic acid and substituted thiazolidinecarboxylic acid are disclosed as angiotensin converting enzyme inhibitors by Ondetti in U.S. Pat. No. 4,192,878 and by Yoshitomo Pharmaceutical Ind. in Belgian Patent No. 868,532.
This invention is directed to new phosphonate substituted amino or imino acids of formula I and salts thereof ##STR2##
X is an imino or amino acid of the formula ##STR3##
R4 is hydrogen, lower alkyl, halogen, keto, hydroxy, ##STR4## a 1- or 2-naphthyl of the formula ##STR5## a 1- or 2-naphthyloxy of the formula ##STR6## or a 1- or 2-naphthylthio of the formula ##STR7##
R5 is keto, halogen, ##STR8## --O--lower alkyl, a 1- or 2-naphthyloxy of the formula ##STR9## --S--lower alkyl, ##STR10## or a 1- or 2-naphthylthio of the formula ##STR11##
R7 is keto or ##STR12##
Each R8 is independently halogen or --Y--R14.
R9, R9 ', R10 and R10 ' are independently selected from hydrogen and lower alkyl or R9 ', R10 and R10 ' are hydrogen and R9 is ##STR13##
R11 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl.
R12 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy.
m is zero, one, two or three.
p is one, two or three provided that p is more than one only if R11 or R12 is hydrogen, methyl, methoxy, chloro, or fluoro.
R13 is hydrogen or lower alkyl of 1 to 4 carbons.
Y is oxygen or sulfur.
R14 is lower alkyl of 1 to 4 carbons, ##STR14## or the R14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di(lower alkyl of 1 to 4 carbons) substituent.
R21 is hydrogen, lower alkyl, cycloalkyl, phenyl, or ##STR15##
R22 is hydrogen, lower alkyl, ##STR16##
r is an integer from 1 to 4.
R1 is alkyl of 1 to 10 carbons, aminoalkyl, haloalkyl, ##STR17## wherein q is zero or an integer from 1 to 7 and R12 and p are as defined above.
R19 and R20 are independently selected from hydrogen, lower alkyl, halo substituted lower alkyl, ##STR18## wherein m, R11, and p are as defined above.
R2 is hydrogen, lower alkyl, halo substituted lower alkyl, ##STR19## wherein r is as defined above.
R3 and R6 are independently selected from hydrogen, lower alkyl, benzyl, alkali metal such as Li, Na or K, benzhydryl, or ##STR20## wherein R15 is hydrogen, lower alkyl, cycloalkyl, or phenyl, and R16 is hydrogen, lower alkyl, lower alkoxy, phenyl, or R15 and R16 taken together are --(CH2)2 --, --(CH2)3 --, --CH═CH--, or ##STR21##
R17 is lower alkyl, benzyl, or phenethyl.
R18 is hydrogen, lower alkyl, benzyl or phenethyl.
This invention in its broadest aspects relates to the phosphonate substituted imino or amino acid compounds of formula I above, to compositions containing such compounds and to the method of using such compounds as anti-hypertensive agents.
The term alkyl used in defining R1 refers to straight or branched chain hydrocarbon radicals having up to ten carbons, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, heptyl, octyl, decyl, etc. The term lower alkyl used in defining various symbols refers to straight or branched chain radicals having up to seven carbons. The preferred lower alkyl groups are up to four carbons with methyl and ethyl most preferred. Similarly the terms lower alkoxy and lower alkylthio refer to such lower alkyl groups attached to an oxygen or sulfur.
The term cycloalkyl refers to saturated rings of 3 to 7 carbon atoms with cyclopentyl and cyclohexyl being most preferred.
The term halo refers to Cl, Br and F. The term halo substituted lower alkyl refers to such lower alkyl groups described above in which one or more hydrogens have been replaced by chloro, bromo or fluoro groups such as trifluoromethyl, which is preferred, pentafluoroethyl, 2,2,2-trichloroethyl, chloromethyl, bromomethyl, etc. Similarly, the term amino substituted lower alkyl refers to lower alkyl groups in which one or more hydrogens have been replaced by --NH2, i.e., aminomethyl, 2-aminoethyl, etc. The symbols ##STR22## represent that the alkylene bridge is attached to an available carbon atom.
The compounds of formula I wherein R1 is other than ##STR23## are prepared according to the following procedures. A phosphonic acid of formula II ##STR24## wherein R1 is as defined above is treated with a chlorinating agent such as phosphorus pentachloride in the presence of an inert organic solvent such as benzene to form a compound of the formula ##STR25## which is reacted with a lactate of the formula ##STR26## in the presence of an organic base such as triethylamine followed by an alcohol R3 OH (where R3 is lower alkyl, benzyl, or benzhydryl) to form a compound of the formula ##STR27## The formula V compound is then treated with strong base such as sodium hydroxide or lithium hydroxide in a mixture of water and an organic solvent such as dioxane to form the corresponding acid ##STR28##
The acid VI or its activated form is then coupled with an imino or amino acid or ester of the formula ##STR29## The term activated form refers to the conversion of the acid to a mixed anhydride, symmetrical anhydride, acid chloride, or activated ester, see Methoden der Organischen Chemie (Houben-Weyl), Vol. XV, part II, page 1 et seq. (1974) for a review of the methods of acylation. Preferably the reaction is performed in the presence of a coupling agent such as 1,1-carbonyldiimidazole, thionyl chloride, or dicyclohexylcarbodiimide.
In the above reaction if R2 is ##STR30## then the hydroxyl, amino, imidazolyl, mercaptan, or guanidinyl function should be protected during the coupling reaction. Suitable protecting groups include benzyloxycarbonyl, t-butoxycarbonyl, benzyl, benzhydryl, trityl, etc., and nitro in the case of guanidinyl. The protecting group is removed by hydrogenation, treatment with acid, or other known methods following completion of the reaction.
Similarly, if in the above reaction R1 =aminoalkyl, then the amino group should be similarly protected, preferably by phthalidyl. The protecting group is removed by treatment with hydrazine following completion of the reaction.
The products of formula I wherein either or both of R3 and R6 are lower alkyl, benzyl, or benzhydryl can be hydrogenated, for example, by treating with hydrogen in the presence of a palladium on carbon catalyst or chemically treated such as with sodium hydroxide in aqueous dioxane or with trimethylsilylbromide in dichloromethane to yield the products of formula I wherein R3 and R6 are hydrogen.
The ester products of formula I wherein R6 is ##STR31## may be obtained by employing the imino or amino acid of formula V in the above reactions with the ester group already in place. Such ester reactants can be prepared by treating peptide, imino, or amino acids with an acid chloride such as ##STR32## so as to protect the N-atom. The protected acid compound is then reacted in the presence of base with a compound of the formula ##STR33## wherein L is a leaving group such as chlorine, bromine, tolylsulfonyloxy, etc., followed by removal of the N-protecting group such as by treatment with acid or hydrogenation.
The ester products of formula I wherein R6 is ##STR34## can also be obtained by treating the product of formula I wherein R6 is hydrogen with a molar equivalent of the compound of formula VIII. The diester products wherein R3 and R6 are the same and are ##STR35## can be obtained by treating the product of formula I wherein R3 and R6 are both hydrogen or an alkali metal salt with two or more equivalents of the compound of formula VIII.
The ester products of formula I wherein R3 is ##STR36## can be obtained by treating the product of formula I wherein R3 is hydrogen or an alkali metal salt and R6 is benzyl or benzhydryl with the compound of formula VIII in the presence of base. Removal of the R6 ester group such as by hydrogenation yields the products of formula I wherein R3 is ##STR37## and R6 is hydrogen.
The products of formula I wherein R4 is amino may be obtained by reducing the corresponding products of formula I wherein R4 is azido.
The various imino and amino acids and esters of formula V are described in the literature and in the various patents and pending U.S. application referred to above. Various substituted prolines are also disclosed by Mauger et al., Chem. Review, Vol. 66, p. 47-86 (1966). When the amino or imino acid is known, it can be readily converted to the ester by conventional means. For example, the esters where R6 is t-butyl can be obtained by treating the corresponding N-carbobenzyloxyimino acid with isobutylene under acidic conditions and then removing the N-carbobenzyloxy protecting group by catalytic hydrogenation and the esters wherein R6 is benzyl can be obtained by treating the imino acid with benzyl alcohol and thionyl chloride.
As disclosed by Krapcho in U.S. Ser. No. 164,985, the substituted prolines wherein R4 is ##STR38## are prepared by reacting a 4-keto proline of the formula ##STR39## with a solution of the Grignard or lithium reagent ##STR40## wherein R4 is as defined above and halo is Br or Cl to yield ##STR41## This compound is treated with a dehydrating agent such as p-toluenesulfonic acid, sulfuric acid, potassium bisulfate, or trifluoroacetic acid to yield the 3,4-dehydro-4-substituted proline of the formula ##STR42## Removal of the N-benzyloxycarbonyl protecting group and hydrogenation of the compound of formula XII yields the desired starting materials. The substituted proline wherein R4 is cyclohexyl can be prepared by further hydrogenation of the 4-phenyl proline compound.
The substituted prolines wherein R4 is the substituted amino group ##STR43## may be prepared by reacting a 4-keto proline of formula IX with the amine ##STR44## in the presence of hydrogen and catalyst or in the presence of sodium cyanotrihydridoborate.
The compounds of formula I wherein R1 is ##STR45## that is ##STR46## may be prepared by reacting an aminophosphonic acid of the formula ##STR47## with an acid chloride having the formula ##STR48## such as benzoyl chloride, in the presence of an inert organic solvent, such as dioxane and a weak organic base, such as triethylamine to yield ##STR49## The formula XVI compound is then coupled with an imino or amino acid or ester of formula XVII ##STR50## in the presence of a coupling agent, such as dicyclohexylcarbodiimide as described above to form ##STR51##
Where X includes a protecting group, it may be removed by hydrogenation wherein the protecting group is phenylmethoxycarbonyl or by treatment with hydrazine where the protecting group is phthalidyl to yield the compounds of formula XIII.
The compounds of formula XVII may be prepared by coupling a hydroxy acid of formula XIX as the free acid or corresponding sodium salt ##STR52## with an imino or amino ester of formula VII preferably in the presence of a coupling agent such as diphenyl phosphorylazide.
Preferred compounds of this invention with respect to the amino or imino acid or ester part of the structure of formula I are those wherein:
R21 is hydrogen, methyl, phenyl, cyclopentyl or cyclohexyl;
R22 is hydrogen, lower alkyl of 1 to 4 carbons, ##STR53## R6 is hydrogen, an alkali metal salt, or ##STR54## R15 is hydrogen, methyl or isopropyl and R16 is straight or branched chain lower alkyl of 1 to 4 carbons or phenyl.
R4 is hydrogen.
R4 is hydroxy.
R4 is chloro or fluoro.
R4 is lower alkyl of 1 to 4 carbons or cyclohexyl.
R4 is amino.
R4 is --O--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R4 is ##STR55## wherein m is zero, one or two, R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R4 is ##STR56## 1-naphthyloxy, or 2-naphthyloxy wherein m is zero, one or two, and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R4 is --S--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R4 is ##STR57## 1-naphthylthio, or 2-naphthylthio wherein m is zero, one or two, and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R5 is --O--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R5 is ##STR58## wherein m is zero, one or two, and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R5 is --S--lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R5 is ##STR59## wherein m is zero, one or two, and R12 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R7 is phenyl, 2-hydroxyphenyl, or 4-hydroxyphenyl.
Each R8 is independently fluoro or chloro.
Each R8 is independently --Y--R14 wherein Y is O or S, R14 is straight or branched chain alkyl of 1 to 4 carbons or the R14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a methyl or dimethyl substituent.
R9, R9 ', R10 and R10 ' are all hydrogen, or R9 is phenyl, 2-hydroxyphenyl or 4-hydroxyphenyl and R9 ', R10 and R10 ' are hydrogen.
Most preferred compounds of this invention with respect to the amino or imino acid or ester part of the structure of formula I are those wherein: ##STR60##
R6 is hydrogen, ##STR61## or an alkali metal salt.
R4 is hydrogen.
R4 is cyclohexyl.
R4 is lower alkoxy of 1 to 4 carbons.
R4 is ##STR62## wherein m is zero, one, or two and R11 is hydrogen, methyl, methoxy, methylthio, Cl, Br, F or hydroxy.
Y is oxygen or sulfur and t is two or three, especially wherein Y is sulfur and t is two.
Preferred compounds of this invention with respect to the phosphonyl sidechain of the structure of formula I are those wherein:
R2 is hydrogen, lower alkyl of 1 to 4 carbons, CF3, or amino substituted lower alkyl of 1 to 4 carbons, especially hydrogen, methyl or --(CH2)4 NH2.
R3 is hydrogen, an alkali metal salt, lower alkyl of 1 to 4 carbons, or ##STR63## wherein R15 is hydrogen, methyl or isopropyl and R16 is straight or branched chain lower alkyl of 1 to 4 carbons or phenyl, especially hydrogen, alkali metal salt, ethyl, ##STR64##
R1 is alkyl of 1 to 10 carbons; ##STR65## wherein q is zero or an integer from 1 to 4 and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy; --(CH2)q -- cycloalkyl wherein cycloalkyl is of 5 or 6 carbons and q is zero, one or two; ##STR66## wherein q is zero or an integer from 1 to 4, ##STR67## wherein q is zero or an integer from 1 to 4, ##STR68## wherein q is zero or an integer from 1 to 4 or ##STR69##
R19 and R20 are independently selected from lower alkyl of 1 to 4 carbons or ##STR70## wherein q is zero or an integer from 1 to 4 and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy, especially wherein R19 is phenylethyl and R20 is phenyl.
The compounds of this invention wherein at least one of R3 or R6 is hydrogen, form basic salts with various inorganic and organic bases which are also within the scope of the invention. Such salts include ammonium salts, alkali metal salts like lithium, sodium and potassium salts (which are preferred), alkaline earth metal salts like calcium and magnesium salts, salts with organic bases, e.g., dicyclohexylamine salt, benzathine, N-methyl-D-glucamine, hydrabamine salts, salts with amino acids like arginine, lysine and the like. The nontoxic physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product. The salts are formed using conventional techniques.
As shown above, the amino or imino acid or ester portion of the molecule of the products of formula I represented by X is in the L-configuration. Depending upon the definition of R2 and R19 other asymmetric center may be present in the phosphonyl sidechain. Thus, some of the compounds can accordingly exist in diastereoisomeric forms or in mixtures thereof. The above described processes can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric products are prepared, they can be separated by conventional chromatographic or fractional crystallization methods.
The products of formula I wherein the imino acid ring is monosubstituted give rise to cis-trans isomerism. The configuration of the final product will depend upon the configuration of the R4, R5 and R7 substituent in the starting material.
The compounds of formula I, and the physiologically acceptable salts thereof, are hypotensive agents. They inhibit the conversion of the decapeptide angiotensin I to angiotensin II and, therefore, are useful in reducing or relieving angiotensin related hypertension. The action of the enzyme renin on angiotensinogen, a pseudoglobulin in blood pressure, produces angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in several forms of hypertension in various mammalian species, e.g., humans. The compounds of this invention intervene in the angiotensinogen→(renin)→angiotensin I→angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II. Thus by the administration of a composition containing one (or a combination) of the compounds of this invention, angiotensin dependent hypertension in a species of mammal (e.g., humans) suffering therefrom is alleviated. A single dose, or preferably two or four divided daily doses, provided on a basis of about 0.1 to 100 mg per kilogram of body weight per day is appropriate to reduce blood pressure. The substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes can also be employed.
The compounds of this invention can also be formulated in combination with a diuretic for the treatment of hypertension. A combination product comprising a compound of this invention and a diuretic can be administered in an effective amount which comprises a total daily dosage of about 30 to 600 mg., preferably about 30 to 330 mg of a compound of this invention, and about 15 to 300 mg, preferably about 15 to 200 mg of the diuretic, to a mammalian species in need thereof. Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds.
The compounds of formula I can be formulated for use in the reduction of blood pressure in compositions such as tablets, capsules or elixirs for oral administration, or in sterile solutions or suspensions for parenteral administration. About 10 to 500 mg of a compound of formula I is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservatives, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
The following examples are illustrative and present preferred embodiments of the invention. Temperatures are given in degrees centigrade. AG-50W-X8 refers to a crosslinked polystyrenedivinylbenzene sulfonic acid cation exchange resin. HP-20 refers to a porous crosslinked polystyrene-divinyl benzene polymer resin.
A mixture of 4-phenylbutyl chloride (8.0 g, 47.5 mmole) and triethylphosphite (15.0 ml, 72 mmole) was heated at reflux (bath temperature 185° C.) under argon for 41.5 hours. Distillation of the mixture gave pure diethyl (4-phenylbutyl)phosphonate (10.8 g, 84%) as a colorless liquid, b.p. 152°-154° C. (1.0 mmHg). TLC (EtOAc) single spot Rf =0.55.
A mixture of diethyl (4-phenylbutyl)phosphonate (3.5 g, 13.0 mmole) and 6 N HCl (45 ml) was refluxed under argon for 16 hours. The cooled reaction mixture was extracted with EtOAc. The organic phase was washed with saturated NaCl, dried (MgSO4), and evaporated. The crude product (2.3 g) was recrystallized from diisopropyl ether to give pure (4-phenylbutyl)phosphonic acid (1.7 g, 61%) as white needles, m.p. 92°-93° C.
Analysis Calcd for C10 H15 O3 P: C, 56.07; H, 7.06; P, 14.46. Found: C, 55.83; H, 7.04; P. 14.34.
A mixture of 4-phenylbutyl phosphonic acid from Part A (0.70 g, 3.27 mmole), benzene (10 ml), and PCl5 (1.36 g, 6.54 mmole) was refluxed under argon for 30 minutes. The benzene and POCl3 were removed in vacuo and the residue taken up in CH2 Cl2 (5 ml). After cooling to 0° C. (ice-bath), triethylamine (1.3 ml, 9.39 mmole) was added followed by dropwise treatment with d,1 ethyl lactate (0.39 ml, 3.3 mmole) in CH2 Cl2 (3 ml) over a 5 minute period. After 1 hour benzyl alcohol (0.35 ml, 3.3 mmole) in CH2 Cl2 (3 ml) was added dropwise over 2 minutes, the ice-bath removed, and the reaction mixture allowed to stir for 2 hours. The reaction mixture was diluted with EtOAc then washed with H2 O, 5% KHSO4, saturated NaHCO3, brine, dried (MgSO.sub. 4), and evaporated. The residue (1.3 g) was chromatographed on silica (70 g) eluting with 2/1 hexane/EtOAc to obtain the title compound (0.80 g, 1.98 mmole; 60% yield) as an oil.
TLC (2/1 hexane/EtOAc) two isomers Rf =0.25, 0.20.
A mixture of the ethyl ester from Part B (0.80 g, 1.98 mmole), 1 N NaOH (3.0 ml, 3.0 mmole) and dioxane (10 ml) was stirred at 25° C. in an argon atmosphere for 2 hours. The reaction mixture was diluted with H2 O and then washed with EtOAc. The aqueous phase was acidified to pH=1.0 with concentrated HCl and the resulting oil was extracted into EtOAc. The ETOAc extract was washed with brine, dried (MgSO4), and evaporated to give the title compound (0.70 g, 1.86 mmole, 94% yield) as an oil.
TLC (1/9 CH3 OH/CH2 Cl2) major spot Rf =0.5.
A mixture of mono acid from Part C (0.70 g, 1.86 mmole), 1,1-carbonyldiimidazole (0.30 g, 1.85 mmole) and dry THF (10 ml) was stirred at 0° C. in an argon atmosphere for 1 hour. Triethylamine (0.26 ml, 1.88 mmole) and L-proline, phenylmethyl ester, hydrochloride salt (commercially available) (0.45 g, 1.86 mmole) were added to the resulting imidazolide and the ice-bath removed. After 60 hours the reaction mixture was diluted with EtOAc, then washed with H2 O, 5% KHSO4, saturated NaHCO3, brine, dried (MgSO4), and evaporated. The residue (850 mg) was chromatographed on silica (45 g) eluting with 5/2 hexane/acetone to obtain the title compound (0.40 g, 0.71 mmole, 38% yield) as an oil.
TLC (5/2 hexane/acetone) single spot Rf =0.2.
A mixture of the dibenzyl ester from Part D (0.40 g, 0.71 mmole), 10% Pd/C (50 mg), and CH3 OH (40 ml) was hydrogenated on the Parr apparatus at 50 psi for 3 hours. The catalyst was removed by filtration (celite bed) and the filtrate was evaporated. The residue was taken up in H2 O (2 ml) and 0.1 M Li2 CO3 (3.5 ml, 0.35 mmole) and passed through an AG50WX8 (Li) (40 ml) column. The desired fractions were combined, filtered (millipore), and lyophilized to give the title product (245 mg, 0.62 mmole, 87% yield) as a glassy solid.
TLC (7/2/1 isopropanol/conc. NH4 OH/H2 O) single spot Rf =0.8.
Analysis calcd for C18 H24 NO6 P.2 Li.1.0 mole H2 O: C, 52.31; H, 6.34; N, 3.39; P, 7.5. Found: C, 52.44; H, 6.14; N, 3.63; P, 7.2.
To a stirred solution of benzyl carbamate (15 g, 0.1 mole) and phosphorus trichloride (9 ml, 0.1 mole) in glacial acetic acid (25 ml) at 0° (ice bath), there is added 3-phenylpropanol (20 g, 0.149 mole) dropwise over a period of 30 minutes. The resulting mixture is stirred at 0° for 15 minutes and then allowed to warm to room temperature. The mixture is then refluxed for 30 minutes, treated with 4 N hydrochloric acid (125 ml) and again refluxed for one hour. After cooling, the aqueous solution is decanted from the dark organic layer, washed with ethyl acetate, and evaporated to dryness. The residue is taken up in water (50 ml) and again evaporated to dryness. This is repeated two more times. Finally, the solid residue is triturated with acetonitrile-water and dried in vacuo over phosphorus pentoxide to give 10.05 g of (1-amino-3-phenylpropyl)phosphonic acid as a white crystalline solid; m.p. 274°-278° (dec.).
A mixture of amino phosphonic acid prepared in Part A (3.2 g, 14.9 mmole), dioxane (20 ml), H2 O (8.0 ml), and triethylamine (7.5 ml, 54.2 mmole) at 0° C. (ice bath) was treated dropwise with benzoyl chloride (2.8 ml, 19.4 mmole) in dioxane (4.0 ml) over a 5 minute period. The ice bath was removed and the reaction mixture stirred for 2 hours, diluted with H2 O, and then washed with Et2 O. The aqueous phase was acidified to pH 1.0 with concentrated HCl and the resulting oil was extracted into EtOAc (3x), washed with brine, dried (MgSO4), and evaporated. The residue was stirred under Et2 O/hexane to give a gummy solid, from which upon trituration with IPE (2x) the title compound (4.0 g, 12.5 mmole, 84% yield) was obtained as a white crystalline solid, m.p. 166°-168° C.
TLC (7:2:1, Isopropanol/conc. NH4 OH/H2 O) major spot, Rf =0.4.
Analysis Calcd for C10 H13 NO4 P: N, 4.39; C. 60.10; H, 5.68; P, 9.7. Found: N, 4.34; C, 60.30; H, 5.83; P, 9.6.
A mixture of sodium lactate (1.7 g, 15.0 mmole), diphenyl phosphorylazide (3.6 ml, 16.5 mmole) and dry DMF (30 ml) at 0° C. (ice bath) in an argon atmosphere was treated with triethyl amine (2.1 ml, 15.2 mmole) and L-proline, phenylmethyl ester, hydrochloride salt (3.6 g, 15.0 mmole). After 24 hours, the reaction mixture was partitioned between EtOAc and H2 O. The aqueous phase was back extracted, the organic extracts combined, washed with 5% KHSO4, brine, and evaporated. The residue (5.0 g) was chromatographed on silica (130 g) eluting the EtOAc/Hexane (1:1) to give the title compound (2.5 g, 9.0 mmole, 60% yield) as a white crystalline solid after evaporation, m.p. 86°-88° C.
Analysis Calcd for C15 H19 NO4 : N, 5.05; C, 64.97; H, 6.91. Found: N, 5.02; C, 64.70; H, 6.85.
A mixture of the phosphonic acid from Part B (0.60 g, 1.9 mmole), lactoyl proline, phenylmethyl ester (from Part C) (0.52 g, 1.9 mmole), and dry THF (5 ml) at 0° C. under argon was treated with dicyclohexylcarbodiimide (0.39 g, 1.9 mmole). After 15 minutes, the reaction mixture was diluted with EtOAc and filtered to remove the dicyclohexylurea. The filtrate was washed with 5% KHSO4, brine, dried (MgSO4), and evaporated. The residue (1.2 g) was chromatographed on silica (60 g) eluting with (20:1:1, CH2 Cl2 /CH3 OH/HOAc). The desired fractions were combined and evaporated to dryness to give the title compound (1.0 g, 1.7 mmole, 90% yield) as a foam. TLC: (20:1:1, CH2 Cl2 /CH3 OH/HOAc) two isomers Rf =0.15, 0.20.
A mixture of the phosphonic monoester from Part D (1.0 g, 1.7 mmole), 10% Pd/C (400 mg), and CH3 OH (50 ml) was hydrogenated on the Parr apparatus at 50 psi for 1.5 hours. The catalyst was removed by filtration (Celite bed) and the solvent evaporated. The residue was taken up in 1 N LiOH (2.5 ml, 2.5 mmole) and applied to an AG50Wx8 (Li) (50 ml) column eluting with H2 O. The desired fractions were combined, evaporated to small volume, and chromatographed on an HP-20 (200 ml) column eluting with a linear gradient H2 O/CH3 CN (0→90% CH3 CN). The desired fractions were combined, evaporated to dryness, taken up in H2 O, filtered (millipore), and lyophilized to give the title product (0.51 g, 1.0 mmole, 60% yield) as a white solid. TLC: (7:2:1, Isopropanol/conc. NH2 OH/H2 O) single spot Rf =0.7, m.p. 248°-255° C.
Analysis Calcd for C24 H27 N2 O7 PLi2.0.74 moles of H2 O
Calcd: N, 5.45; C, 56.12; H, 5.59; P, 6.0. Found: N, 5.35; C, 56.12; H, 5.66; P, 6.0.
Following the procedure of Example 1 but employing the phosphonic acid shown in Col. I, the lactate shown in Column II, the imino acid or amino acid or ester in Col. III, and the alcohol R3 OH, one obtains the diester shown in Col. IV. Both the R3 and R6 ester groups may be removed to yield the corresponding diacid or salt as set forth in Example 1E or only the carboxylic ester group R6 may be removed or in the case of Examples 77-87 only the R3 ester group may be removed.
______________________________________
Col. I Col. III
______________________________________
##STR71##
##STR72##
______________________________________
Col. III Col. IV
______________________________________
HX
##STR73##
______________________________________
__________________________________________________________________________
Ex.
R.sub.1 R.sub.3 R.sub.2 X
__________________________________________________________________________
3. H.sub.3 C(CH.sub.2).sub.5
##STR74##
##STR75##
##STR76##
4. H.sub.3 C
##STR77##
CH.sub.3
##STR78##
5. H.sub.5 C.sub.2
##STR79##
H
##STR80##
##STR81##
##STR82##
CH.sub.3
##STR83##
##STR84##
##STR85##
##STR86##
##STR87##
##STR88##
##STR89##
CH.sub.3
##STR90##
##STR91##
##STR92##
##STR93##
##STR94##
10.
##STR95##
##STR96##
##STR97##
##STR98##
##STR99##
##STR100##
CF.sub.3
##STR101##
##STR102##
##STR103##
CH.sub.3
##STR104##
##STR105##
##STR106##
H
##STR107##
##STR108##
##STR109##
CH.sub.3
##STR110##
##STR111##
##STR112##
CH.sub.3
##STR113##
##STR114##
##STR115##
CH.sub.3
##STR116##
##STR117##
##STR118##
CH.sub.3
##STR119##
##STR120##
##STR121##
CF.sub.3
##STR122##
##STR123##
##STR124##
CH.sub.3
##STR125##
20.
##STR126##
##STR127##
CH.sub.3
##STR128##
##STR129##
##STR130##
CH.sub.3
##STR131##
H.sub.3 C(CH.sub.2).sub.6
##STR132##
CH.sub.3
##STR133##
H.sub.3 C(CH.sub.2).sub.3
##STR134##
CH.sub.3
##STR135##
##STR136##
##STR137##
CH.sub.3
##STR138##
##STR139##
##STR140##
H
##STR141##
##STR142##
##STR143##
CH.sub.3
##STR144##
##STR145##
##STR146##
CH.sub.3
##STR147##
##STR148##
##STR149##
CH.sub.3
##STR150##
##STR151##
##STR152##
CH.sub.3
##STR153##
30.
##STR154##
##STR155##
CH.sub.3
##STR156##
##STR157##
##STR158##
CH.sub.3
##STR159##
##STR160##
##STR161##
CH.sub.3
##STR162##
##STR163##
##STR164##
CH.sub.3
##STR165##
##STR166##
##STR167##
CH.sub.3
##STR168##
##STR169##
##STR170##
CH.sub.3
##STR171##
H.sub.3 C
##STR172##
CH.sub.3
##STR173##
H.sub.5 C.sub.2
##STR174##
CH.sub.3
##STR175##
##STR176##
##STR177##
CH.sub.3
##STR178##
##STR179##
##STR180##
CH.sub.3
##STR181##
40.
##STR182##
##STR183##
CH.sub.3
##STR184##
-41.
##STR185##
##STR186##
CH.sub.3
##STR187##
H.sub.3 C(CH.sub.2).sub.5
##STR188##
H
##STR189##
##STR190##
##STR191##
CH.sub.3
##STR192##
##STR193##
##STR194##
##STR195##
##STR196##
##STR197##
##STR198##
CH.sub.3
##STR199##
##STR200##
##STR201##
CH.sub.3
##STR202##
##STR203##
##STR204##
CH.sub.3
##STR205##
##STR206##
##STR207##
CH.sub.3
##STR208##
H.sub.3 C(CH.sub.2).sub.3
##STR209##
CH.sub.3
##STR210##
50.
##STR211##
##STR212##
CH.sub.3
##STR213##
##STR214##
##STR215##
CH.sub.3
##STR216##
##STR217##
##STR218##
CH.sub.3
##STR219##
##STR220##
##STR221##
CH.sub.3
##STR222##
##STR223##
##STR224##
CH.sub.3
##STR225##
##STR226##
##STR227##
CH.sub.3
##STR228##
H.sub.3 C(CH.sub.2).sub.3
##STR229##
CH.sub.3
##STR230##
##STR231##
##STR232##
CH.sub.3
##STR233##
##STR234##
##STR235##
CH.sub.3
##STR236##
H.sub.3 C(CH.sub.2).sub.5
##STR237##
CH.sub.3
##STR238##
60.
##STR239##
##STR240##
CH.sub.3
##STR241##
##STR242##
##STR243##
CH.sub.3
##STR244##
##STR245##
##STR246##
H
##STR247##
##STR248##
##STR249##
CH.sub.3
##STR250##
##STR251##
##STR252##
CH.sub.3
##STR253##
H.sub.3 C(CH.sub.2).sub.4
##STR254##
CH.sub.3
##STR255##
##STR256##
##STR257##
H
##STR258##
##STR259##
##STR260##
CH.sub.3
##STR261##
##STR262##
##STR263##
C.sub.2 H.sub.5
##STR264##
##STR265##
##STR266##
CH.sub.3
##STR267##
70.
H.sub.3 C(CH.sub.2).sub.5
##STR268##
CH.sub.3
##STR269##
##STR270##
##STR271##
CH.sub.3
##STR272##
##STR273##
##STR274##
CH.sub.3
##STR275##
##STR276##
##STR277##
CH.sub.3
##STR278##
##STR279##
##STR280##
CH.sub.3
##STR281##
##STR282##
##STR283##
CH.sub.3
##STR284##
H.sub.3 C(CH.sub.2).sub.5
##STR285##
H
##STR286##
##STR287##
##STR288##
CH.sub.3
##STR289##
##STR290##
##STR291##
CH.sub.3
##STR292##
H.sub.3 C(CH.sub.2).sub.5
##STR293##
CH.sub.3
##STR294##
80.
##STR295##
##STR296##
CH.sub.3
##STR297##
##STR298##
##STR299##
CH.sub.3
##STR300##
##STR301##
##STR302##
CH.sub.3
##STR303##
##STR304##
##STR305##
CH.sub.3
##STR306##
##STR307##
##STR308##
CH.sub.3
##STR309##
##STR310##
##STR311##
CH.sub.3
##STR312##
##STR313##
##STR314##
CH.sub.3
##STR315##
##STR316##
##STR317##
CH.sub.3
##STR318##
##STR319##
##STR320##
CH.sub.3
##STR321##
##STR322##
##STR323##
CH.sub.3
##STR324##
90.
H.sub.3 C(CH.sub.2).sub.5
##STR325##
H
##STR326##
##STR327##
##STR328##
CH.sub.3
##STR329##
##STR330##
##STR331##
CH.sub.3
##STR332##
##STR333##
##STR334##
CH.sub.3
##STR335##
H.sub.5 C.sub.2
##STR336##
CH.sub.3
##STR337##
##STR338##
##STR339##
CH.sub.3
##STR340##
##STR341##
##STR342##
CH.sub.3
##STR343##
##STR344##
##STR345##
CH.sub.3
##STR346##
##STR347##
##STR348##
CH.sub.3
##STR349##
##STR350##
##STR351##
CH.sub.3
##STR352##
100.
##STR353##
##STR354##
CH.sub.3
##STR355##
101.
H.sub.3 C(CH.sub.2).sub.5
##STR356##
CH.sub.3
##STR357##
102.
##STR358##
##STR359##
H
##STR360##
103.
H.sub.3 C(CH.sub.2).sub.5
##STR361##
CH.sub.3
##STR362##
104.
H.sub.3 CCH.sub.2
##STR363##
C.sub.2 H.sub.5
##STR364##
105.
##STR365##
##STR366##
H
##STR367##
__________________________________________________________________________
Following the procedure of Example 2 but employing the phosphonic acid shown in Col. I, the acid chloride shown in Col. II, and the hydroxyacyl imino ester shown in Col. III, one obtains the intermediate shown in Col. IV. Removal of the carboxylic acid protecting group yields the compound of Col. V which can be treated to obtain a salt as shown in Example 2, Part E.
______________________________________
Col. I Col. II Col. III
______________________________________
##STR368##
##STR369##
##STR370##
______________________________________
Col. IV
______________________________________
##STR371##
______________________________________
Col. V
______________________________________
##STR372##
______________________________________
__________________________________________________________________________
Ex.
R.sub.19 R.sub.2 X R.sub.20
__________________________________________________________________________
106.
##STR373##
CH.sub.3
##STR374##
##STR375##
107.
##STR376##
CH.sub.3
##STR377##
##STR378##
108.
##STR379##
CH.sub.3
##STR380## H.sub.3 C
109.
##STR381##
CH.sub.3
##STR382##
##STR383##
110.
##STR384##
CH.sub.3
##STR385##
##STR386##
111.
##STR387##
CH.sub.3
##STR388## F.sub.3 C
112.
##STR389##
CH.sub.3
##STR390## H
113.
CH.sub.3 CH.sub.3
##STR391##
##STR392##
114.
##STR393##
CH.sub.3
##STR394##
##STR395##
115.
##STR396##
CH.sub.3
##STR397##
##STR398##
116.
##STR399##
CH.sub.3
##STR400##
##STR401##
117.
##STR402##
CH.sub.3
##STR403##
##STR404##
118.
H CH.sub.3
##STR405##
##STR406##
119.
##STR407##
##STR408##
##STR409##
##STR410##
120.
##STR411##
CH.sub.3
##STR412##
##STR413##
121.
##STR414##
H
##STR415##
##STR416##
122.
##STR417##
H
##STR418##
##STR419##
123.
##STR420##
C.sub.2 H.sub.5
##STR421##
##STR422##
124.
##STR423##
CH.sub.3
##STR424##
##STR425##
__________________________________________________________________________
Following the procedure of Example 1, Part D, using L-proline, 1,1-dimethylethyl ester in place of L-proline, phenylmethyl ester gives the title compound.
A mixture of the benzyl ester from Part A (1.03 g, 2.0 mmole) 10% Pd/C (0.20 g) and methanol (50 ml) is hydrogenated on a Parr apparatus at a pressure of 50 psi for 3 hours. The catalyst is removed by filtration through celite and the filtrate evaporated to dryness to give the title compound.
A solution of the monoacid from Part B (0.64 g, 1.5 mmole), triethylamine (0.42 ml, 3.0 mmole) and chloromethyl pivalate (0.45 g, 3.0 mmole) in dry dimethylformamide (5 ml) is stirred at room temperature under argon for 16 hours. The mixture is then partitioned between EtOAc-water. The organic phase is washed successively with 5% KHSO4, saturated NaHCO3 and saturated NaCl, dried over Na2 SO4 and evaporated. The crude product is purified by flash chromatography on silica gel to give the title compound.
A solution of the diester from Part C (0.54 g, 1.0 mmole) and anisole (2 ml) in CH2 Cl2 (10 ml) is treated with trifluoroacetic acid (5 ml) at 0° C. (ice bath). After 1 hour at 0° C., the mixture is partitioned between EtOAc-water. The organic phase is washed with water and saturated NaCl, dried over Na2 SO4 and evaporated. The crude product is purified by flash chromatography on silica gel to give the title compound.
Following the procedure of Example 125 but employing the alkylating agent shown in Col. I in place of the chloromethyl pivalate, one obtains the product in Col. II.
______________________________________
Ex. Col. I Col. II
______________________________________
126.
##STR426## (±)-1-[2-[[[(Acetyloxy)- methoxy](4-phenylbutyl)-
phosphinyl]oxy]-1-oxopropyl]- L-proline
127.
##STR427## (±)-1-[2-[[[1-(Ethoxycarbonyl- oxy)ethoxy](4-phen
ylbutyl)- phosphinyl]oxy]-1-oxopropyl]- L-proline
128.
##STR428## (±)-1-[2-[[(3-Oxo-1-iso- benzofuranyloxy)(4-pheny
l- butyl)phosphinyl]oxy]-1- oxopropyl]-L-proline
129.
##STR429## (±)-1-[2-[[[(Benzoyloxy)- methoxy](4-phenylbutyl)
- phosphinyl]oxy]-1-oxopropyl]- L-proline
130.
##STR430## (±)-1-[2-[[[2-Methyl-1- (1-oxopropoxy)propoxy](4-
phenylbutyl)phosphinyl]oxy]- 1-oxopropyl]-L-proline
______________________________________
Similarly, the alkylating agents of Examples 125-130 can be employed with the appropriately protected compounds of Examples 1 to 124 to yield other compounds within the scope of this invention. In the cases where the proline carboxyl group is protected as its phenylmethyl ester rather than its t-butyl ester, it is removed by hydrogenation in the presence of Pd/C in the final step.
Following the procedure of Example 1 but substituting AG-50W-X8 (Na+) for the lithium resin in Part E, one obtains the title product.
This procedure can be employed in Examples 2-130 to give the corresponding mono or disodium salt. Similarly, by employing a potassium resin the corresponding mono or dipotassium salt is obtained.
1000 Tablets each containing the following ingredients:
______________________________________
(±)-[2-[[Hydroxy(4-phenylbutyl)-
100 mg
phosphinyl]oxy]-1-oxopropyl]-
L-proline, disodium salt
Corn starch 50 mg
Gelatin 7.5 mg
Avicel (microcrystalline 25 mg
cellulose)
Magnesium stearate 2.5 mg
185 mg
______________________________________
are prepared from sufficient bulk quantities by mixing the (±)-[2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxopropyl]-L-proline, disodium salt and corn starch with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with granulation. This mixture is then compressed in a tablet to form 1000 tablets each containing 100 mg of active ingredient.
In a similar manner, tablets containing 100 mg of the product of any of Examples 2 to 130 can be prepared.
1000 tablets each containing the following ingredients:
______________________________________
1-[(S)--2-[[[(±)-1-(Benzoylamino)-
50 mg
3-phenylpropyl]phosphinyl]oxy]-
1-oxopropyl]-L-proline, sodium salt
Lactose 25 mg
Avicel 38 mg
Corn starch 15 mg
Magnesium stearate 2 mg
130 mg
______________________________________
are prepared from sufficient bulk quantities by mixing the 1-[(S)-2-[[[(±)-1-(benzoylamino)-3-phenylpropyl]phosphinyl]oxy]-1-oxopropyl]-L-proline, sodium salt, lactose and Avicel and then blending with the corn starch. Magnesium stearate is added and the dry mixture is compressed in a tablet press to form 1000 tablets each containing 50 mg of active ingredient. The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake containing yellow #6.
In a similar manner, tablets containing 50 mg of the product of any of Examples 1 and 3 to 130 can be prepared.
Two piece #1 gelatin capsules each containing 100 mg of 1-[(S)-2-[[[(±)-1-(benzoylamino)-3-phenylpropyl]phosphinyl]oxy]-1-oxopropyl]-L-proline, sodium salt are filled with a mixture of the following ingredients:
______________________________________
1-[(S)--2-[[[(±)-1-(Benzoylamino)-3-
100 mg
phenylpropyl]phosphinyl]oxy]-1-
oxopropyl]-L-proline, sodium salt
Magnesium stearate 7 mg
Lactose 193 mg
300 mg
______________________________________
In a similar manner, capsules containing 100 mg of the product of any of Examples 1 and 3 to 130 can be prepared.
An injectable solution is prepared as follows:
______________________________________
(±)-1-[2-[[Hydroxy(4-phenylbutyl)-
500 g
phosphinyl]oxy]-1-oxopropyl]-
L-proline, disodium salt
Methyl paraben 5 g
Propyl paraben 1 g
Sodium chloride 25 g
Water for injection 5 l
______________________________________
The active substance, preservatives, and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and asceptically filled into presterilized vials which are closed with presterilized rubber closures. Each vial contains 5 ml of solution in a concentration of 100 mg of active ingredient per ml of solution for injection.
In a similar manner, an injectable solution containing 100 mg of active ingredient per ml of solution can be prepared for the product of any of Examples 2 to 130.
1000 Tablets each containing the following ingredients:
______________________________________
(±)-1-[2-[[Hydroxy(4-phenylbutyl)-
100 mg
phosphinyl]oxy]-1-oxopropyl]-
L-proline, disodium salt
Avicel 100 mg
Hydrochlorothiazide 12.5 mg
Lactose 113 mg
Corn starch 17.5 mg
Stearic acid 7 mg
350 mg
______________________________________
are prepared from sufficient bulk quantities by slugging the (±)-1-[2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxopropyl]-L-proline, disodium salt, Avicel and a portion of the stearic acid. The slugs are ground and passed through a #2 screen, then mixed with the hydrochlorothiazide, lactose, corn starch, and remainder of the stearic acid. The mixture is compressed into 350 mg capsule shaped tablets in a tablet press. The tablets are scored for dividing in half.
In a similar manner, tablets can be prepared containing 100 mg of the product of any of Examples 2 to 130.
Claims (22)
1. A compound of the formula ##STR431## and pharmaceutically acceptable salts thereof wherein: ##STR432## R4 is hydrogen, lower alkyl, halogen, keto, hydroxy, ##STR433## azido, amino, ##STR434## a 1- or 2-naphthyl of the formula ##STR435## --(CH2)m --cycloalkyl, ##STR436## --O--lower alkyl, ##STR437## a 1- or 2-naphthyloxy of the formula ##STR438## --S--lower alkyl, ##STR439## or a 1- or 2-naphthylthio of the formula ##STR440##
R5 is keto, halogen, ##STR441## --O--lower alkyl, a 1- or 2-naphthyloxy of the formula ##STR442## --S--lower alkyl, ##STR443## or a 1- or 2-naphthylthio of the formula ##STR444## R7 is keto or ##STR445## each R8 is the same or different and is halogen or --Y--R14 ; R11 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl;
R12 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy;
m is zero, one, two or three;
p is one, two or three provided that p is more than one only if R11 or R12 is hydrogen, methyl, methoxy, chloro, or fluoro;
R13 is hydrogen or lower alkyl of 1 to 4 carbons;
Y is oxygen or sulfur;
R14 is lower alkyl of 1 to 4 carbons, ##STR446## or the R14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di(lower alkyl of 1 to 4 carbons) substituent;
R1 is alkyl of 1 to 10 carbons, aminoalkyl, haloalkyl, ##STR447## wherein q is zero or an integer from 1 to 7 and R11 and p are as defined above; and
R19 and R20 are independently selected from the group consisting of hydrogen, lower alkyl, halo substituted lower alkyl, ##STR448## wherein m, R11 and p are as defined above; R2 is hydrogen, lower alkyl, halo substituted lower alkyl, ##STR449## wherein r is as defined hereinbefore; R3 and R6 are independently selected from hydrogen, lower alkyl, benzyl, benzhydryl, alkali metal, or ##STR450## wherein R15 is hydrogen, lower alkyl, cycloalkyl, or phenyl, and R16 is hydrogen, lower alkyl, lower alkoxy, phenyl, or R15 and R16 taken together are --(CH2)2 --, --(CH2)3, --CH═CH-- or ##STR451## R17 is lower alkyl, benzyl, or phenethyl; and R18 is hydrogen, lower alkyl, benzyl, or phenethyl.
2. A compound of claim 1 wherein:
R4 is hydrogen, hydroxy, chloro, fluoro, lower alkyl of 1 to 4 carbons, cyclohexyl, amino, --O--lower alkyl wherein lower alkyl is of 1 to 4 carbons, ##STR452## 1- or 2-naphthyloxy, --S--lower alkyl wherein lower alkyl is of 1 to 4 carbons, ##STR453## or 1- or 2-naphthylthio; R5 is --O--lower alkyl wherein lower alkyl is of 1 to 4 carbons, --S--lower alkyl wherein lower alkyl is of 1 to 4 carbons, ##STR454## R7 is phenyl, 2-hydroxyphenyl, or 4-hydroxyphenyl; each R8 is fluoro, chloro or --Y--R14 ;
Y is oxygen or sulfur;
R14 is lower alkyl of 1 to 4 carbons or the R14 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a methyl or dimethyl substituent;
m is zero, one or two;
R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy;
R2 is hydrogen, lower alkyl of 1 to 4 carbons, CF3, or amino substituted lower alkyl of 1 to 4 carbons;
R1 is alkyl of 1 to 10 carbons, ##STR455## --(CH2)q --cycloalkyl wherein cycloalkyl is of 5 or 6 carbons, ##STR456## wherein q is zero or an integer from 1 to 4 and R11 is as defined above;
R19 and R20 are independently selected from lower alkyl of 1 to 4 carbons or ##STR457## wherein q and R11 are as defined above; R3 and R6 are independently selected from hydrogen, alkali metal salt, lower alkyl of 1 to 4 carbons, or ##STR458## R15 is hydrogen, methyl or isopropyl; and R16 is lower alkyl of 1 to 4 carbons or phenyl.
3. A compound of claim 2 wherein X is ##STR459## R4 is hydrogen, cyclohexyl, lower alkoxy of 1 to 4 carbons, ##STR460## m is zero, one or two; R11 is hydrogen, methyl, methoxy, methylthio, bromo, fluoro, or hydroxy;
Y is oxygen or sulfur;
t is two or three; and
R6 is hydrogen, ##STR461## or an alkali metal salt, R1 is ##STR462## R2 is hydrogen or lower alkyl; and R3 is hydrogen, alkali metal or phenylalkyl.
4. A compound of claim 3 wherein
R1 is phenylalkyl or ##STR463## wherein R19 is phenylalkyl and R20 is phenyl; R2 is hydrogen, methyl, or --(CH2)4 --NH2 ; and
R3 is hydrogen, phenylmethyl, ##STR464## or an alkali metal salt.
5. A compound of claim 4 wherein R1 is alkyl of 1 to 10 carbons.
6. A compound of claim 5 wherein X is ##STR465## and R4 is hydrogen.
7. The compound of claim 3 wherein R1 is phenylbutyl; R2 is methyl; and R3 and R6 are an alkali metal salt.
8. The compound of claim 3 wherein R1 is ##STR466## R2 is methyl; and R3 and R6 are an alkali metal salt.
9. The compound of claim 6 wherein R1 is ##STR467## R2 is methyl; R3 is ethyl; and R6 is an alkali metal salt.
10. The compound of claim 6 wherein R1 is ##STR468## R2 is methyl; and R3 and R6 are an alkali metal salt.
11. The compound of claim 6 wherein R1 is ##STR469## R2 is methyl; R3 is ##STR470## and R6 is an alkali metal salt.
12. The compound of claim 6 wherein R1 is ##STR471## R2 is methyl; and R3 and R6 are an alkali metal salt.
13. The compound of claim 6 wherein R1 is ##STR472## R2 is methyl; and R3 and R6 are an alkali metal salt.
14. The compound of claim 6 wherein R1 is ##STR473## R2 is methyl; and R3 and R6 are an alkali metal salt.
15. The compound of claim 6 wherein R1 is ##STR474## R2 is hydrogen; and R3 and R6 are an alkali metal salt.
16. The compound of claim 6 wherein R1 is ##STR475## R2 is hydrogen; and R3 and R6 are an alkali metal salt.
17. The compound of claim 1 wherein X is ##STR476##
18. The compound of claim 1 wherein R1 is ##STR477## and R19 and R20 are independently selected from lower alkyl of 1 to 4 carbons or ##STR478## wherein q is zero or an integer from 1 to 4 and R11 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
19. A compound of claim 18 wherein X is ##STR479## and R4 is hydrogen.
20. A composition useful for treating hypertension comprising a pharmaceutically acceptable carrier and a hypotensive compound or pharmaceutically acceptable salt thereof defined in claim 1.
21. The method of alleviating hypertension in a mammalian specie which comprises administering an effective amount of the composition of claim 20.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/391,884 US4452790A (en) | 1982-06-23 | 1982-06-23 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| CA000430309A CA1248111A (en) | 1982-06-23 | 1983-06-13 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| JP58113603A JPS5916899A (en) | 1982-06-23 | 1983-06-22 | Hypotensive phosphonylhydroxyacylamino acid derivative |
| EP83303592A EP0097534B1 (en) | 1982-06-23 | 1983-06-22 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| AT83303592T ATE37375T1 (en) | 1982-06-23 | 1983-06-22 | PHOSPHONYL HYDROXYACYL AMINO ACID DERIVATIVES AND THEIR USE AS ANTIHYPERTENSIVES. |
| DE8383303592T DE3378052D1 (en) | 1982-06-23 | 1983-06-22 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US06/809,630 US4616005A (en) | 1982-06-23 | 1985-12-16 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US06/849,040 US4703043A (en) | 1982-06-23 | 1985-12-16 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/391,884 US4452790A (en) | 1982-06-23 | 1982-06-23 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06608752 Division | 1984-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4452790A true US4452790A (en) | 1984-06-05 |
Family
ID=23548350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/391,884 Expired - Lifetime US4452790A (en) | 1982-06-23 | 1982-06-23 | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4452790A (en) |
| EP (1) | EP0097534B1 (en) |
| JP (1) | JPS5916899A (en) |
| AT (1) | ATE37375T1 (en) |
| CA (1) | CA1248111A (en) |
| DE (1) | DE3378052D1 (en) |
Cited By (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4616005A (en) * | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US4670422A (en) * | 1986-03-27 | 1987-06-02 | E. R. Squibb & Sons, Inc. | α-acyloxy phosphonate angiotensin converting enzyme inhibitors |
| US4670193A (en) * | 1986-05-12 | 1987-06-02 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonic acids |
| US4686298A (en) * | 1986-03-27 | 1987-08-11 | E. R. Squibb & Sons, Inc. | Intermediates for alpha-acyloxy phosphonate angiotensin converting enzyme inhibitors |
| US4703043A (en) * | 1982-06-23 | 1987-10-27 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
| US4716155A (en) * | 1981-12-24 | 1987-12-29 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and hypotensive use thereof |
| US4740332A (en) * | 1986-05-12 | 1988-04-26 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonous acids |
| US4745196A (en) * | 1986-01-06 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Orally active phosphonyl hydroxyacyl prolines |
| USH642H (en) | 1984-08-20 | 1989-06-06 | E. R. Squibb & Sons, Inc. | Substituted urido amino and imino acids and esters |
| US4849414A (en) * | 1986-06-11 | 1989-07-18 | E. R. Squibb & Sons, Inc. | Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors |
| US4885380A (en) * | 1986-03-13 | 1989-12-05 | Thottathil John K | Process for preparing phosphonyloxyacyl amino acids and derivatives thereof |
| EP0344995A2 (en) * | 1988-06-01 | 1989-12-06 | E.R. SQUIBB & SONS, INC. | Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor |
| US4900860A (en) * | 1986-03-13 | 1990-02-13 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonyloxyacyl amino acids |
| US4931430A (en) * | 1987-12-14 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Method for preventing or treating anxiety employing an ACE inhibitor |
| US4963539A (en) * | 1987-09-10 | 1990-10-16 | E. R. Squibb & Sons, Inc. | Phosphonate and phosphonamide endopeptidase inhibitors |
| US5015633A (en) * | 1987-04-27 | 1991-05-14 | E. R. Squibb & Sons, Inc. | Method for inhibiting loss of cognitive functions employing an ace inhibitor |
| US5030648A (en) * | 1990-01-12 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Combination and method for treating obsessive-compulsive disorder, and motor and phonic tics in Tourettes' syndrome using such combination |
| US5032578A (en) * | 1990-09-17 | 1991-07-16 | E. R. Squibb & Sons, Inc. | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| US5093129A (en) * | 1989-01-30 | 1992-03-03 | E. R. Squibb & Sons, Inc. | Method for treating addiction to a drug of abuse employing an ace inhibitor |
| US5098889A (en) * | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
| US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
| USH1286H (en) | 1989-06-05 | 1994-02-01 | E. R. Squibb & Sons, Inc. | Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof |
| US5504070A (en) * | 1991-12-05 | 1996-04-02 | Berlex Laboratories, Inc. | Inhibitors of the conversion of big endothelin to endothelin |
| US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US5880112A (en) * | 1996-06-17 | 1999-03-09 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6025344A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| US6372726B1 (en) | 1996-06-17 | 2002-04-16 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using NAALADase inhibitors |
| US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| US6458775B1 (en) | 1998-07-06 | 2002-10-01 | Guilford Pharmaceutical Inc. | NAALADase inhibitors useful as pharmaceutical compounds and compositions |
| US20030225091A1 (en) * | 2001-11-16 | 2003-12-04 | Magnin David R. | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| US20040167197A1 (en) * | 2003-02-26 | 2004-08-26 | Rudolph Amy E. | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| US20040266831A1 (en) * | 2003-06-11 | 2004-12-30 | Robinson Leslie A. | Modulators of the glucocorticoid receptor and method |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| US20050085497A1 (en) * | 2003-09-25 | 2005-04-21 | Saleem Ahmad | HMG-CoA reductase inhibitors and method |
| US20050171140A1 (en) * | 2003-11-20 | 2005-08-04 | O'connor Stephen P. | HMG-CoA reductase inhibitors and method |
| WO2007073503A2 (en) | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| WO2008057857A1 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| US20090177267A1 (en) * | 2007-11-15 | 2009-07-09 | David Paul Biggs | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| EA012845B1 (en) * | 2005-12-09 | 2009-12-30 | Менарини Интернэшнл Оперейшнс Люксембург С. А. | Pharmaceutical compositions comprising zofenopril and hctz for treating hypertension |
| US20100286365A1 (en) * | 2007-09-27 | 2010-11-11 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US8759295B2 (en) | 2006-03-21 | 2014-06-24 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427665A (en) * | 1982-05-19 | 1984-01-24 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions |
| EP0209848A3 (en) * | 1985-07-24 | 1988-07-27 | Merck & Co. Inc. | Enzyme inhibitors |
| FI870896A (en) * | 1986-03-13 | 1987-09-14 | Squibb & Sons Inc | FOERFARANDE FOER FRAMSTAELLNING AV FOSFONYLOXIACYLAMINOSYROR OCH DERAS DERIVAT. |
| EP0239109A3 (en) * | 1986-03-27 | 1989-03-22 | E.R. Squibb & Sons, Inc. | Phosphonate angiotensin converting enzyme inhibitors |
| CA1307787C (en) * | 1986-06-11 | 1992-09-22 | Melanie J. Loots | Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors |
| CA1306749C (en) * | 1986-07-14 | 1992-08-25 | Donald S. Karanewsky | .alpha.-ACYLAMINO AMINOALKYL PHOSPHONATE ANGIOTENSIN CONVERTING ENZYME INHIBITORS |
| CA1321753C (en) * | 1987-04-27 | 1993-08-31 | Abraham Sudilovsky | Method for inhibiting loss of cognitive functions employing an ace inhibitor |
| NZ225757A (en) * | 1987-09-10 | 1989-12-21 | Squibb & Sons Inc | Phosphonate and phosphonamide endopeptidase inhibitors |
| EP0335770B1 (en) * | 1988-04-01 | 1997-01-15 | Merrell Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| DE4125440A1 (en) * | 1990-08-09 | 1992-02-13 | Sandoz Ag | MONO, BI OR TRI-CARBOCYCLIC PHOSPHINE OR PHOSPHONIC ACID COMPOUNDS |
| JPH0538638A (en) * | 1991-08-01 | 1993-02-19 | Kawaju Tekko Koji Kk | Box column provisional assembling device for box column assembly line |
Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053651A (en) * | 1976-05-10 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Compounds and method for alleviating angiotensin related hypertension |
| US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| BE868532A (en) * | 1977-06-29 | 1978-10-16 | Yoshitomi Pharmaceutical | NEW DERIVATIVES OF THIAZOLIDINE |
| US4129566A (en) * | 1978-02-15 | 1978-12-12 | E. R. Squibb & Sons, Inc. | Derivatives of dehydrocyclicimino acids |
| US4151172A (en) * | 1977-08-11 | 1979-04-24 | E. R. Squibb & Sons, Inc. | Phosphonoacyl prolines and related compounds |
| US4154935A (en) * | 1978-02-21 | 1979-05-15 | E. R. Squibb & Sons, Inc. | Halogen substituted mercaptoacylamino acids |
| US4168267A (en) * | 1978-10-23 | 1979-09-18 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl prolines |
| GB2027025A (en) * | 1978-08-02 | 1980-02-13 | Santen Pharmaceutical Co Ltd | Antihypertensive 5-substituted 2-pyrrolidine-carboxylic acid and salts thereof |
| GB2028327A (en) * | 1978-08-11 | 1980-03-05 | Squibb & Sons Inc | Mercaptoacyl derivatives of substituted prolines |
| US4192878A (en) * | 1976-12-03 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Derivatives of thiazolidinecarboxylic acids and related acids |
| EP0009183A1 (en) * | 1978-09-07 | 1980-04-02 | Merck & Co. Inc. | Phosphoryl aminoacid derivatives and composition for treating hypertension containing the same |
| US4199512A (en) * | 1976-05-10 | 1980-04-22 | E. R. Squibb & Sons, Inc. | Compounds for alleviating hypertension |
| US4217359A (en) * | 1979-01-15 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Carbamate derivatives of mercaptoacyl hydroxy prolines |
| GB2039478A (en) * | 1978-12-22 | 1980-08-13 | Squibb & Sons Inc | Derivatives of mercaptoacyl pyrrolidines or piperidines |
| US4234489A (en) * | 1979-06-25 | 1980-11-18 | E. R. Squibb & Sons, Inc. | Pyroglutamic acid derivatives and analogs |
| US4256761A (en) * | 1979-07-13 | 1981-03-17 | Usv Pharmaceutical Corporation | Antihypertensive amides |
| US4296033A (en) * | 1980-07-23 | 1981-10-20 | E. R. Squibb & Sons, Inc. | 4-Azido-1-mercaptoacyl proline |
| US4296113A (en) * | 1980-01-14 | 1981-10-20 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid |
| US4303583A (en) * | 1979-08-13 | 1981-12-01 | American Home Products Corporation | 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones |
| US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
| US4374131A (en) * | 1981-04-27 | 1983-02-15 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinyl-alkanoyl compounds |
| US4379146A (en) * | 1981-02-17 | 1983-04-05 | Merck & Co., Inc. | Substituted phosphonamides as antihypertensives |
| US4381297A (en) * | 1981-05-04 | 1983-04-26 | E. R. Squibb & Sons, Inc. | Substituted carbonyl phosphinyl-alkanoyl compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4555506A (en) * | 1981-12-24 | 1985-11-26 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and use as hypotensives |
-
1982
- 1982-06-23 US US06/391,884 patent/US4452790A/en not_active Expired - Lifetime
-
1983
- 1983-06-13 CA CA000430309A patent/CA1248111A/en not_active Expired
- 1983-06-22 EP EP83303592A patent/EP0097534B1/en not_active Expired
- 1983-06-22 DE DE8383303592T patent/DE3378052D1/en not_active Expired
- 1983-06-22 JP JP58113603A patent/JPS5916899A/en active Granted
- 1983-06-22 AT AT83303592T patent/ATE37375T1/en active
Patent Citations (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053651A (en) * | 1976-05-10 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Compounds and method for alleviating angiotensin related hypertension |
| US4199512A (en) * | 1976-05-10 | 1980-04-22 | E. R. Squibb & Sons, Inc. | Compounds for alleviating hypertension |
| US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| US4192878A (en) * | 1976-12-03 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Derivatives of thiazolidinecarboxylic acids and related acids |
| BE868532A (en) * | 1977-06-29 | 1978-10-16 | Yoshitomi Pharmaceutical | NEW DERIVATIVES OF THIAZOLIDINE |
| US4151172A (en) * | 1977-08-11 | 1979-04-24 | E. R. Squibb & Sons, Inc. | Phosphonoacyl prolines and related compounds |
| US4129566A (en) * | 1978-02-15 | 1978-12-12 | E. R. Squibb & Sons, Inc. | Derivatives of dehydrocyclicimino acids |
| US4154935A (en) * | 1978-02-21 | 1979-05-15 | E. R. Squibb & Sons, Inc. | Halogen substituted mercaptoacylamino acids |
| GB2027025A (en) * | 1978-08-02 | 1980-02-13 | Santen Pharmaceutical Co Ltd | Antihypertensive 5-substituted 2-pyrrolidine-carboxylic acid and salts thereof |
| GB2028327A (en) * | 1978-08-11 | 1980-03-05 | Squibb & Sons Inc | Mercaptoacyl derivatives of substituted prolines |
| EP0009183A1 (en) * | 1978-09-07 | 1980-04-02 | Merck & Co. Inc. | Phosphoryl aminoacid derivatives and composition for treating hypertension containing the same |
| US4316896A (en) * | 1978-09-07 | 1982-02-23 | Merck & Co., Inc. | Aminoacid derivatives as antihypertensives |
| US4168267A (en) * | 1978-10-23 | 1979-09-18 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl prolines |
| GB2039478A (en) * | 1978-12-22 | 1980-08-13 | Squibb & Sons Inc | Derivatives of mercaptoacyl pyrrolidines or piperidines |
| US4217359A (en) * | 1979-01-15 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Carbamate derivatives of mercaptoacyl hydroxy prolines |
| US4234489A (en) * | 1979-06-25 | 1980-11-18 | E. R. Squibb & Sons, Inc. | Pyroglutamic acid derivatives and analogs |
| US4256761A (en) * | 1979-07-13 | 1981-03-17 | Usv Pharmaceutical Corporation | Antihypertensive amides |
| US4256761B1 (en) * | 1979-07-13 | 1984-10-09 | ||
| US4303583A (en) * | 1979-08-13 | 1981-12-01 | American Home Products Corporation | 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones |
| US4296113A (en) * | 1980-01-14 | 1981-10-20 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid |
| US4296033A (en) * | 1980-07-23 | 1981-10-20 | E. R. Squibb & Sons, Inc. | 4-Azido-1-mercaptoacyl proline |
| US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
| US4379146A (en) * | 1981-02-17 | 1983-04-05 | Merck & Co., Inc. | Substituted phosphonamides as antihypertensives |
| US4374131A (en) * | 1981-04-27 | 1983-02-15 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinyl-alkanoyl compounds |
| US4381297A (en) * | 1981-05-04 | 1983-04-26 | E. R. Squibb & Sons, Inc. | Substituted carbonyl phosphinyl-alkanoyl compounds |
Non-Patent Citations (6)
| Title |
|---|
| Galardy, "Inhibition of Angiotensin . . . " Biochem. Biophs. Res. Comm., 1980, vol. 97, pp. 94-99. |
| Galardy, Inhibition of Angiotensin . . . Biochem. Biophs. Res. Comm., 1980, vol. 97, pp. 94 99. * |
| Mauger, "Analogs and Homologs of Proline . . . ", Chem. Review, vol. 66, pp. 47-86 (1966). |
| Mauger, Analogs and Homologs of Proline . . . , Chem. Review, vol. 66, pp. 47 86 (1966). * |
| Thorsett et al., "Phosphorus Containing Inhibitors . . . ", 182 National Meeting, ACS, New York, Aug. 1981, MEDI-7, Proc. Natl. Acad. Sci., USA, vol. 79, pp. 2176-2180 (04/82). |
| Thorsett et al., Phosphorus Containing Inhibitors . . . , 182 National Meeting, ACS, New York, Aug. 1981, MEDI 7, Proc. Natl. Acad. Sci., USA, vol. 79, pp. 2176 2180 (04/82). * |
Cited By (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716155A (en) * | 1981-12-24 | 1987-12-29 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and hypotensive use thereof |
| US4616005A (en) * | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US4703043A (en) * | 1982-06-23 | 1987-10-27 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
| USH642H (en) | 1984-08-20 | 1989-06-06 | E. R. Squibb & Sons, Inc. | Substituted urido amino and imino acids and esters |
| US4745196A (en) * | 1986-01-06 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Orally active phosphonyl hydroxyacyl prolines |
| AU592390B2 (en) * | 1986-01-06 | 1990-01-11 | E.R. Squibb & Sons, Inc. | Orally active phosphonyl hydroxyacyl prolines and processes for preparing phosphonyl hydroxyacyl prolines |
| EP0350138A2 (en) | 1986-01-06 | 1990-01-10 | E.R. SQUIBB & SONS, INC. | Processes for preparing phosphonyl hydroxyacyl prolines |
| US4885380A (en) * | 1986-03-13 | 1989-12-05 | Thottathil John K | Process for preparing phosphonyloxyacyl amino acids and derivatives thereof |
| US4900860A (en) * | 1986-03-13 | 1990-02-13 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonyloxyacyl amino acids |
| US4670422A (en) * | 1986-03-27 | 1987-06-02 | E. R. Squibb & Sons, Inc. | α-acyloxy phosphonate angiotensin converting enzyme inhibitors |
| US4686298A (en) * | 1986-03-27 | 1987-08-11 | E. R. Squibb & Sons, Inc. | Intermediates for alpha-acyloxy phosphonate angiotensin converting enzyme inhibitors |
| US4740332A (en) * | 1986-05-12 | 1988-04-26 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonous acids |
| US4670193A (en) * | 1986-05-12 | 1987-06-02 | E. R. Squibb & Sons, Inc. | Process for preparing phosphonic acids |
| US4849414A (en) * | 1986-06-11 | 1989-07-18 | E. R. Squibb & Sons, Inc. | Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors |
| US5015633A (en) * | 1987-04-27 | 1991-05-14 | E. R. Squibb & Sons, Inc. | Method for inhibiting loss of cognitive functions employing an ace inhibitor |
| US4963539A (en) * | 1987-09-10 | 1990-10-16 | E. R. Squibb & Sons, Inc. | Phosphonate and phosphonamide endopeptidase inhibitors |
| US4931430A (en) * | 1987-12-14 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Method for preventing or treating anxiety employing an ACE inhibitor |
| EP0344995A2 (en) * | 1988-06-01 | 1989-12-06 | E.R. SQUIBB & SONS, INC. | Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor |
| EP0344995A3 (en) * | 1988-06-01 | 1990-12-05 | E.R. SQUIBB & SONS, INC. | Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor |
| US5093129A (en) * | 1989-01-30 | 1992-03-03 | E. R. Squibb & Sons, Inc. | Method for treating addiction to a drug of abuse employing an ace inhibitor |
| USH1286H (en) | 1989-06-05 | 1994-02-01 | E. R. Squibb & Sons, Inc. | Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof |
| US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
| US5030648A (en) * | 1990-01-12 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Combination and method for treating obsessive-compulsive disorder, and motor and phonic tics in Tourettes' syndrome using such combination |
| US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
| US5032578A (en) * | 1990-09-17 | 1991-07-16 | E. R. Squibb & Sons, Inc. | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| US5098889A (en) * | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5504070A (en) * | 1991-12-05 | 1996-04-02 | Berlex Laboratories, Inc. | Inhibitors of the conversion of big endothelin to endothelin |
| US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6025344A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US5880112A (en) * | 1996-06-17 | 1999-03-09 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors |
| US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6479471B1 (en) | 1996-06-17 | 2002-11-12 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5968915A (en) * | 1996-06-17 | 1999-10-19 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors |
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US6372726B1 (en) | 1996-06-17 | 2002-04-16 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using NAALADase inhibitors |
| US6025345A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US6271245B1 (en) | 1997-04-04 | 2001-08-07 | Guilford Pharmaceuticals, Inc. | Hydroxamic acid derivatives |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6288046B1 (en) | 1997-04-24 | 2001-09-11 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| US6458775B1 (en) | 1998-07-06 | 2002-10-01 | Guilford Pharmaceutical Inc. | NAALADase inhibitors useful as pharmaceutical compounds and compositions |
| US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| US20030064912A1 (en) * | 1998-07-06 | 2003-04-03 | Slusher Barbara S. | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors |
| US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| US6984645B2 (en) | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US20030225091A1 (en) * | 2001-11-16 | 2003-12-04 | Magnin David R. | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| US20040167197A1 (en) * | 2003-02-26 | 2004-08-26 | Rudolph Amy E. | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| US20040266831A1 (en) * | 2003-06-11 | 2004-12-30 | Robinson Leslie A. | Modulators of the glucocorticoid receptor and method |
| US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| US20050085497A1 (en) * | 2003-09-25 | 2005-04-21 | Saleem Ahmad | HMG-CoA reductase inhibitors and method |
| US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US20050171140A1 (en) * | 2003-11-20 | 2005-08-04 | O'connor Stephen P. | HMG-CoA reductase inhibitors and method |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EA012845B1 (en) * | 2005-12-09 | 2009-12-30 | Менарини Интернэшнл Оперейшнс Люксембург С. А. | Pharmaceutical compositions comprising zofenopril and hctz for treating hypertension |
| WO2007073503A2 (en) | 2005-12-21 | 2007-06-28 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| US8759295B2 (en) | 2006-03-21 | 2014-06-24 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| WO2008057857A1 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| US20100286365A1 (en) * | 2007-09-27 | 2010-11-11 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| US20090177267A1 (en) * | 2007-11-15 | 2009-07-09 | David Paul Biggs | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| US7828840B2 (en) | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
| WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
| WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0425274B2 (en) | 1992-04-30 |
| CA1248111A (en) | 1989-01-03 |
| DE3378052D1 (en) | 1988-10-27 |
| EP0097534A3 (en) | 1984-12-12 |
| ATE37375T1 (en) | 1988-10-15 |
| EP0097534A2 (en) | 1984-01-04 |
| EP0097534B1 (en) | 1988-09-21 |
| JPS5916899A (en) | 1984-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4452790A (en) | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives | |
| US4555506A (en) | Phosphorus containing compounds and use as hypotensives | |
| US4616005A (en) | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives | |
| US4716155A (en) | Phosphorus containing compounds and hypotensive use thereof | |
| US5849732A (en) | Phenol compound having antioxidative activity and the process for preparing the same | |
| US4942169A (en) | Piperidine derivative and pharmaceutical composition | |
| US4021224A (en) | Herbicide compositions | |
| US4432971A (en) | Phosphonamidate compounds | |
| US4381297A (en) | Substituted carbonyl phosphinyl-alkanoyl compounds | |
| US5827875A (en) | Inhibitors of microsomal triglyceride transfer protein and method | |
| US6022893A (en) | Hydroxamic acid derivatives | |
| US5731434A (en) | Endothelin antagonists | |
| US5120746A (en) | Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same | |
| US5672596A (en) | Benzo-fused lactams promote release of growth hormone | |
| US4452791A (en) | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors | |
| US5164372A (en) | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same | |
| US5616592A (en) | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them | |
| US4975444A (en) | Cycloalkyl-substituted glutaramide antihypertensive agents | |
| US4405644A (en) | Medicaments for the treatment of disorders of lipometabolism and their use | |
| US5688997A (en) | Process for preparing intermediates for a combinatorial dihydrobenzopyran library | |
| US5719157A (en) | Pharmaceutical composition containing quinoline or quinazoline derivatives | |
| US4376767A (en) | Pyridylmethyl esters of selected bio-affecting carboxylic acids | |
| US4703043A (en) | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive | |
| US6011059A (en) | Acyl guanidine sodium/proton exchange inhibitors and method | |
| US5217972A (en) | Quinolonecarboxylic acid derivatives and their use as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: E.R. SQUIBB & SONS, INC., LAWRENCEVILLE-PRINCETON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KARANEWSKY, DONALD S.;PETRILLO, EDWARD W. JR.;REEL/FRAME:004236/0325 Effective date: 19820819 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| CC | Certificate of correction | ||
| CC | Certificate of correction | ||
| FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |